Dr. Koehler brings over 20 years of oncology drug development leadership experience to Remix's Board of Directors WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical ...
"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix ...
Dr. Reynolds brings over two decades of leadership experience building biotech companies, transformative platforms and drug discovery and development WATERTOWN, Mass., Feb. 1, 2024 /PRNewswire/ -- ...
- REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML - Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to ...
WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback